We reviewed the reports of 784 consecutive patients admitted to our department for newly diagnosed acute myeloid leukemia (AML) over a 16-year period. Median, 5-year and 10-year overall survivals were 9.5 months, 17.3% and 11.7% respectively. Induction treatment (698 patients) resulted in 50% complete remissions (CR) (from 26.5% in secondary AML to 81.2% in patients Ͻ60 years with de novo AML). Period of diagnosis (1980-84/85-89/90-95) demonstrated a major significance for CR achievement and OS in multivariate analysis. In patients у60 years (372), CR rate increased (25% to 36.8%, P = 0.03), and 5-year OS (3.7% to 10.6%, P = 0.022) improved, probably due to an increase in the proportion of patients administered conventional combined chemotherapy (54.5% to 83.8%, P Ͻ 0.0001). In younger patients CR rate continuously increased (61.5% to 74.8%, P = 0.028) with an associated improvement of 5-year OS (19.2% to 35.4%). No significant change in DFS and CR durations was observed. This large single center study on a large cohort of unselected AML patients reflects the improvement achieved in the management of AML patients, likely due to improvement of supportive care practices, administration of conventional induction to more elderly patients, and intensification of induction and post-remission treatments in patients Ͻ60 years.
Introduction
Myelosuppressive induction chemotherapy allows the achievement of complete remission (CR) in the majority of adult patients with acute myelogenous leukemia (AML). 1, 2 However, despite improvements of treatment results achieved since the early 1960s with the use of combination of cytarabine and various intercalating agents, [3] [4] [5] the overall prognosis remains poor. The majority of patients relapse and median CR duration is only 12 to 18 months in most series. Only 10 to 25% of patients experience a long-term disease-free survival (DFS) and the majority of patients still die of the disease. [6] [7] [8] [9] [10] Improvement of the results in patients less than 60 years has been achieved through the intensification of induction/postremission treatments and the availability of intensive supportive care. 9, [11] [12] [13] [14] Allogeneic and autologous bone marrow transplantations have become standard approaches for the management of adult AML patients. 15 Allogeneic BMT is generally proposed to patients aged less than 45-50 years with an HLAidentical sibling, despite the high transplant-related morbidity and mortality, and myeloablative chemotherapy and/or radiation followed by autologous bone marrow or peripheral stem cell transplantation provide interesting results in patients who have no HLA-compatible donor available. [16] [17] [18] [19] However, the indications for transplantation in first complete remission remain controversial. High-dose AraC (HDARAC) either in post-induction or even during induction might also improve long-term perspectives in patients less than 60 years without being necessarily hampered by an increased toxicity over conventional treatment. 9, 12, [20] [21] [22] [23] However, these procedures are restricted so far to suitable patients of appropriate age with good performance status, no comorbidity, and are contraindicated in the elderly because of severe toxicities in this age group. 12 Whether or not elderly AML patients' outcome has improved over the years is still controversial. [24] [25] [26] AML is a heterogeneous disease and therapeutic attitudes vary from intensive induction/post-remission treatments to palliative care according to presentation and disease course. Most of the publications on AML treatment report results of clinical trials and deal with selected patient populations, selection being based on age, performance status and/or preexisting myeloproliferative or myelodysplastic syndrome. As emphasized by some authors, analysis of treatment outcomes and comparison from one series to another is difficult due to differences in patients selection criteria. [27] [28] [29] These differences may sometimes preclude us from drawing conclusions on eventual progress achieved in AML treatment over the years. To avoid this risk of selection bias we decided to retrospectively review the records of all the 784 evaluable patients consecutively admitted to our department for a newly diagnosed, previously untreated AML over a 16 year period (from January 1980 to December 1995). Clinical and biological features at presentation, treatment-related data (treatment allocation, induction regimen results, DFS and overall survival) were analyzed for the whole population, and according to the period of diagnosis (1980 to 1984, 1985 to 1989, 1990 to 1995) and to patient age (у60 or Ͻ60 years). Due to the inclusion of all admitted patients with primary or secondary AML, whatever the leukemic type, the age or any other variable, this retrospective single center study might better reflect the outcome for an unselected population of patients than clinical trials. In addition, it gives some indication on the improvement which has been achieved during this period of time in treatment of patients aged less than 60 years, as well as elderly patients.
Materials and methods

Patients
From January 1980 to December 1995, 806 consecutive adult patients have been referred to our department for newly diagnosed, previously untreated AML. We retrospectively reviewed the clinical and biological characteristics at presentation of these patients, treatment variables (all types of treatment administered including pure supportive care, inclusion into cooperative trials), as well as outcome from the first day of admission. Only 22 reports were excluded from the present study because of lack of adequate data. Diagnosis of AML was established on the basis of bone marrow aspirate (740) or blood (44) smear examination, and AML were classified according to the FAB criteria. 30 Morphological findings were completed by cytochemical and immunologic analyses. In 24 cases FAB subtype could not be precisely determined. De novo AML accounted for 76.9% of cases and secondary for 23.1% (4.9% were secondary to prior chemotherapy and/or radiation therapy for a previous neoplasia, and 8.8% and 9.4% occurred after characterized myeloproliferative disorders and myelodysplastic syndromes, respectively). Adequate cytogenetics routinely performed starting from the late 1980s were available in 474 patients (60.4%). Abnormal karyotypes were grouped into good, intermediate, and poor prognostic categories according to Keating et al. 31 The main initial characteristics of patients are shown in Table 1 .
Treatments
Induction treatment was given to 698 patients while 86 patients remained untreated because of advanced age, poor medical condition and/or early death. Treatment allocation is 32 Briefly, the AML5 trial compared four maintenance treatments based on chemotherapy and/or androgenotherapy and/or immunotherapy. The AML6 trial compared two post-remission treatments (continued administration of daunorubicine (DNR)-AraC combination vs short courses of m-AMSA combined alternately with HDARAC and 5-azacytidine). In the AML8A trial, after DNR-AraC induction and intermediate dose AraC + AMSA consolidation, patients р45 years with an HLA-identical sibling were assigned to allogeneic BMT (alloBMT), while the others were randomized to HDARAC or autologous BMT (ABMT). At the same time, patients aged 46-60 years were included in the AML8B trial comparing the intensive consolidation used in AML8A to the standard treatment of AML6. The AML10 trial (patients р60 years), activated in 1993, is still ongoing and compares three different induction regimens (DNR or mitoxantrone or idarubicine combined with AraC, 10 days, and etoposide, 5 days), then ABMT vs autologous peripheral stem cell (PSC) transplantation after a single intensive consolidation course, while patients Ͻ45 years with an HLA-identical sibling are planned to receive alloBMT. Several successive EORTC trials specific for elderly AML patients have been initiated since 1983, comparing a wait-and-see policy followed by a palliative mild cytoreductive chemotherapy in case of progression to an immediate conventional induction (AML7 trial), then two induction regimens (AraC + mitoxantrone or DNR) and a low-dose AraC maintenance treatment vs no maintenance (AML9 trial), and lately randomizing the use of GM-CSF during induction and until day 28 or neutropenia recovery (AML11 trial). 32 Patients with acute promyelocytic leukemia (APL, FAB-M3) were eligible for inclusion in the EORTC studies with the exception of the AML10 trial. However, with the availability of all-trans retinoic acid, APL patients received this differentiating agent combined or not with chemotherapy as induction treatment following inclusion in two consecutive European trials (APL91 and APL93 trials 33 ) starting from 1991.
Most AML patients Ͻ60 years received chemotherapy exclusively for post-remission treatment, however within the 16-year period 44 patients (16.8% of CR patients) were allografted and 39 patients (14.8% of CR patients) underwent autologous BM (34) or PSC (5) transplantations in CR1, mostly within the prospective randomized trials of the EORTC Cooperative Group. Twenty-three patients treated by chemotherapy after achievement of CR1 were transplanted subsequently in CR2 (14 patients) or in refractory relapse phase (eight first relapse, one second relapse) and one patient with blast crisis of CML was reinfused PSC harvested within chronic phase.
Criteria of response: evaluation
Response to antileukemic therapy was assessed as follows: (1) CR: normal marrow cellularity with less than 5% of blast cells and near-normal peripheral blood counts; (2) resistance: persisting leukemia in blood and/or bone marrow in patients surviving induction regimen more than 1 month; (3) induction death: death occurring within the first month following treatment administration. The duration of disease-free survival (DFS) was measured from the date of CR to the date of relapse or death of any cause, and the duration of overall survival (OS) from the date of diagnosis to the date of death.
Statistical methods
Clinical and biological characteristics, treatment-related data, DFS and OS durations were transferred both to the PCSM program (Deltasoft, Grenoble, Switzerland) on IBMPC2 and to Staview 4-5 on MacIntosh. Analysis was done first for the whole population, and subsequently according to patient's age by separating young (Ͻ60 years) and elderly patients (у60 years), and then to the period of diagnosis and treatment. 5-year periods were arbitrarily chosen (1980 to 1984, 216 patients; 1985 to 1989, 262 patients; 1990 to 1995, 306 patients). Student's t-test and chi-square test were used as appropriate for comparison of continuous and categorical values. DFS and survival were drawn according to Kaplan and Meier 34 and comparison between curves was tested for statistical significance using the two-sided log-rank test. Median follow-up duration was 68 months for the whole population (136 months, 91 months and 35 months for patients diagnosed with AML during the 1980-84, 1985-89, and 1990-95 periods, respectively). Single parameters were investigated for their influence on CR achievement and survival duration. Multivariate analyses were performed using the proportional hazards model.
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Results
Overall survival, treatment allocation and induction treatment results
Overall survival (OS) of all 784 evaluable patients is shown in Figure 1 . Median survival duration for the whole population of patients was 9.5 months with a 5-year OS and a 10-year OS of 17.3% and 11.7%, respectively. Compared with younger patients, elderly patients were characterized by a significantly shorter OS (med: 5 months vs 14 months, 5-year OS: 6.2% vs 25.9%, 10-year OS: 3.0% vs 18.2%, P Ͻ 0.0001). Six hundred and ninety-eight patients (89%) received an induction Overall survival according to age.
Figure 2
Overall survival from date of diagnosis of patients who received induction treatments. Comparison between patients Ͻ60 years and elderly patients. treatment ( Table 2) . Abstention of chemotherapy (86 patients) was more frequent in elderly patients than in younger patients. Thirty-six of the 86 patients with treatment restricted to supportive care died within the first week following the diagnosis. Induction treatments results, OS and DFS of treated patients are shown in Table 3 . Induction treatments resulted in com- Table 3 Results of induction treatment, disease-free survival (DFS) and overall survival (OS) duration according to age Induction treatment results were significantly better in patients aged less than 60 than in elderly patients in terms of CR rate, DFS, CR duration and OS ( Figure 2 , Table 3 ). Conventional induction was administered to most patients aged less than 60 years (89.4%) and only to 69.0% of the elderly patients (P = 0.0001). Among elderly patients, those who received conventional induction were characterized by a higher CR rate (37.5% vs 9.8%, P Ͻ 0.0001) and a trend to longer survival although not significant (5-year OS: 7.3% vs 3.5%, P = 0.051) than patients receiving alternative treatment. Nevertheless, results of conventional induction were significantly poorer in elderly patients than in patients Ͻ60 years in terms of CR rate (37.5% vs 69.3%, P Ͻ 0.0001), 5-year DFS (10.3% vs 27.0%, P = 0.006) and median CR duration (10.5 vs 16.5 months, P Ͻ 0.0001). In the two age groups, the administration of induction treatment following inclusion in phase III clinical trials correlated with a better patient outcome: there were significant differences between patients included and not included in terms of CR rate (patients у60 years: 47.6% vs 19%; patients Ͻ60 years: 77% vs 45.8%; P Ͻ 0.0001) and 5-year OS (patients у60 years: 7.6% vs 4.1%, P = 0.001; patients Ͻ60 years: 33.1% vs 9.1%, P Ͻ 0.0001). Despite the fact that trials specifically designed for elderly patients had been available from the EORTC-LCG since 1983, only 35% of our elderly patients were included in clinical trials, compared to 64.3% of younger patients.
Patients with secondary AML were characterized by poorer induction treatment results than de novo AML patients (CR: 26.5% vs 50.6%; resistance rate: 53.6% vs 28.5%; P Ͻ 0.0001). Secondary AML patients exhibited shorter OS (med: 6 vs 11.5 months; 2-year OS: 6.4% vs 33.2%) and DFS (med: 7 vs 13.5 months; 2-year DFS: 7.6% vs 35.4%) (P Ͻ 0.0001) than de novo AML. As mentioned above, induction treatment results and OS varied markedly according to the subgroup of patients considered. In patients Ͻ60 years with de novo AML and good performance status (WHO-PS 0 to 2) who received conventional induction following inclusion in ongoing clinical trial (202 patients) CR rate was of 81.2% with a median CR duration of 23 months. This subgroup of patients was characterized by the longest DFS (med: 16.5 months; 5-year: 31.2%; 10-year: 21.4%) and OS med: 27 months; 5-year: 36.7%; 10-year: 23.8%) durations.
Results of induction treatments, DFS and OS according to the period of diagnosis and treatment
Analysis of patients' outcome according to date of diagnosis and treatment (1980-84/85-89/90-95) for the whole population indicates a significant improvement of overall CR rate (from 42.9% to 57.1%, P = 0.005) and survival duration (5-year OS: 10.3% to 23.7%; P = 0.002) over the years. From 1980 to 1995, recruitment of patients with newly diagnosed, previously untreated AML remained the same, as well as the proportion of elderly patients and patients mean age ( Table  4) . Comparison of clinical and biological profiles of the populations of patients of the three consecutive periods showed no significant difference with regard to pretreatment character- istics which could have optimized the results of the analysis of patients' outcome in the last period. On the contrary, the proportion of secondary AML or AML occurring after characterized myeloproliferative disorders and myelodysplastic syndromes (in which responses to treatment are poor) significantly increased over the years (from 16.2% to 29.1%, P = 0.002). The two other significant differences we observed between patient subgroups (an increase in the incidence of abnormal karyotypes over the years, and changes in the frequencies of the FAB subtypes) might partly be explained by improvements in the characterization of AML cell features (more sensitive techniques for the detection of cytogenetic abnormalities, immunophenotype). The main differences between patients of the three consecutive periods were related to treatment allocation and rate of inclusion in phase III clinical trials which increased from 40.7% (80-84) to 56.1% for the last period. Continuous improvement of treatment results was observed in patients Ͻ60 years as well as in elderly patients. No matter the period of diagnosis, most of the patients Ͻ60 years received conventional induction (Table 5 ) and CR rate significantly increased from 61.5% to 74.8% (P = 0.028) between 1980-84 and 1990-95 with an associated decrease of the proportion of resistant AML (from 27.5% to 16.1%, P = 0.032), but no change in induction death rate over the years (11.5 ure 3 and Table 5 illustrate the improvement of OS of treated patients Ͻ60 years which nevertheless did not reach statistical significance may be due to the overlap of the origins of the curves. In elderly patients CR rate increased significantly, probably as a result of a marked increase in the proportion of patients receiving conventional induction from one period to another (Table 6) , with in addition an improvement of the results of conventional induction over the years (CR rate ranging from 33.3% to 43.9%). Analysis of outcome of treated patients у60 years according to period of diagnosis also showed a slight but significant improvement of OS duration during the last period 1990-1996 ( Figure 4 , Table 6 ). In the two age groups, no significant improvement of DFS and CR duration was observed over the years. In order to assess whether the improvements achieved depended on AML features we analyzed separately secondary AML (181 patients) and de novo AML (603 patients), no matter the age. The percentage of patients who received conventional induction was lower in secondary AML than in the group of de novo AML (59.1% vs 77.8%). In secondary AML, there was no significant improvement of CR rate from one
-9%). Fig-
Figure 3
Overall survival of patients Ͻ60 years who received induction treatment according to date of diagnosis.
period to another (20%/26.3%/29.2%), however overall survival significantly improved over the years (med: from 4 to 7.5 months; 2-year OS: from 3.8% to 7.8%; P = 0.037). Comparing treated and untreated secondary AML patients we found no significant difference in long-term outcome. Conversely, in de novo AML patients CR rate significantly increased from 47.1% to 66.3% (P Ͻ 0.0001); there was simultaneously a significant increase of OS duration (med: from 11 to 18 months; 5-year OS: from 13.4 to 31.7%, P = 0.005).
The use of all-trans retinoic acid alone or combined with cytotoxic induction chemotherapy has yielded a significant improvement of treatment results in patients with promyelocytic leukemia. 33, 36 Between 1980 and 1995, APL was diagnosed in 53 patients admitted to our department. Induction treatment was administered to 48 of these 53 patients (21M/27F; mean age: 45.8 years, range: 17-84); 18 patients received all-trans retinoic acid combined or not with conventional chemotherapy, mostly (15 patients) following inclusion in the APL91 and APL93 trials (starting from 1991). 33 Comparing the outcome of APL patients admitted within the 1990-95 period (when ATRA became available) (20 patients) with the outcome of APL patients treated before 1990 (28 patients), we observed an increase in CR rate (85 vs 60.7%, P = 0.068) with an associated increase in OS (med: not reached at 46 months for patients of the 1990-95 sub-group vs 35 months for patients of the 1980-89 sub-group; 3-year OS: 55% vs 46.9%) although not significant may be due to the small size of the sub-groups. The significant increase of CR rate and OS duration that we observed for the whole population of patients was the result not only of the improved management of APL patients, but also of the progress achieved for patients diagnosed with AML of other FAB subtypes. For patients of this latter group (all FAB subtypes with the exception of AML3), analysis of patients' outcome showed a significant increase in CR rate (1980-84: 41.6%; 1985-89: 46.2%; 1990-95: 55.0%, P = 0.016) and OS (med: from 7.5 to 12 months; 5-year OS: from 9.4% to 22.3%) over the years. 
Figure 4
Overall survival of elderly patients who received an induction treatment according to date of diagnosis.
Prognostic factors
Several clinical, biological and treatment-related data were analyzed for prognostic significance for achievement of CR, DFS and survival duration for the whole population of patients (Table 7) . Age Ͻ60 years, de novo occurrence of AML, cytogenetics, inclusion in a clinical trial, and administration of conventional induction were major prognostic factors for likelihood of CR achievement, and prolonged DFS and OS. Lower rates of WBC and blood blasts correlated with longer DFS and OS durations but did not demonstrate significance for CR achievement contrary to performance status (OMS Ͻ 2). Having been diagnosed between 1990 and 1995 rather than earlier, significantly correlated with a higher CR rate and longer survival on univariate analysis, but had no significant prognostic value for DFS duration. For the entire cohort, the period of diagnosis still proved a major independent prognostic factor for CR (together with age and inclusion in clinical trials) and survival duration (together with achievement of CR, cytogenetics and performance status) on multivariate analysis. Favorable cytogenetics was the only significant factor for DFS duration on multivariate analysis. Similar analyses were run separately for patients Ͻ60 years and elderly patients, and provided similar results for patients of the two age groups except that de novo AML, cytogenetics and treatment administered (conventional induction vs alternative treatment) demonstrated no significant prognostic value for OS duration in patients у60 years contrary to what was observed in younger patients. In patients aged less than 46 years, accomplishment of a BMT in CR1 correlated with significantly longer OS and DFS. Among elderly patients, age у70 years was associated with a significantly shorter OS and lower probability of CR achievement. Period of diagnosis retained a significant prognostic value for CR achievement and OS duration for patients of the two age groups (Ͻ60 and у60 years).
Discussion
The present study on 784 consecutive unselected patients admitted in a single center for newly diagnosed, previously untreated AML over a 16 year period was aimed at depicting the outcome of AML patients and the eventual improvement achieved in the management of AML patients in the last decades more accurately than reports on clinical trials dealing with selected patient populations. Due to the inclusion of all AML patients whatever the leukemic type, the age or any other variable the overall outcome of the patients of this series is poor, however the significant improvement achieved in treatment of AML is highlighted.
According to most reports, 70-80% of adult patients with AML achieve CR after combined chemotherapy. 1, 2, 8 Effects of selection, most of the time based on age, performance status and de novo vs 'secondary' AML, on treatment results have been highlighted by some studies. [27] [28] [29] In addition, in most series data on poor prognostic patients to whom no chemotherapy was administered are missing which biases analysis of AML prognosis. Very few population-based analyses were reported due to lack of registries in AML. 35 However, very likely, most AML patients aged less than 60 are admitted in specialized units once diagnosis is made, whereas a larger proportion of elderly AML patients are not referred to hematooncology departments. Among patients of our series 47.5% were aged 60 years or more, 19.9% presented with poor performance status, and 23.1% were 'secondary AML'. These fea- All the parameters that demonstrated significance on univariate analysis were considered for multivariate analysis. P values for parameters which retained independent prognostic value on multivariate analysis are indicated in bold characters.
tures are close to those reported in epidemiological or descriptive studies. 25, 37, 38 We did not exclude from the present study any of the 86 patients (10.9%) with treatment restricted to supportive care because of advanced age, poor medical condition and/or early death; in addition, a long follow-up allowed us to also take into account late relapses. As a result, the overall survival and overall treatment outcome observed for the whole population of patients were distinctly worse than those reported in most published series. When restricting analysis to patients aged less than 60 years with de novo AML and who received conventional induction, we observed a high CR rate and DFS and OS durations similar to those reported in clinical trials. 2, 8, 9, 12, [39] [40] [41] This study shows that significant improvements in the management of AML patients have been achieved. Being diagnosed and treated between 1990 and 1995 rather than earlier demonstrated a major prognostic significance on multivariate analysis for CR achievement and OS duration. The similar clinical and biological profiles of the populations of patients diagnosed with AML during the three consecutive periods of times that we compared, suggest that there was no inherent bias with regard to pretreatment characteristics which could have optimized the results of the analysis of patients outcome in the last period. On the contrary, if any, the influence of the differences that we observed between the sub-groups (higher incidences of secondary AML and abnormal karyotypes for the 1990-95 period) would have underestimated the improvements achieved. Therefore we believe that the significant progress we observed across the three consecutive 5-year periods were due to changes in therapeutic practices. Most patients aged less than 60 years admitted to our department were treated according to the AML5 or AML6 EORTC trials (pilot phase or randomized phase III) between 1980 and 1984, and subsequently (1985-95) to the AML8 and AML10 protocols, corresponding to an increase of the dose-intensity of the anthracycline + AraC combined induction from a '1+7' ADRAraC to a '3+10+5' days anthracycline-AraC-VP16 schedule. 32 Thus, together with the improvement of supportive care, intensification of induction regimens in patients aged less than 60 years have contributed very likely to the significant continuous improvement of CR rate (from 61.5% to 74.8%, P = 0.028) with an associated improvement of 5-year OS (19.2% to 35.4%) although not significant (may be due to the overlap of the origins of the curves). In our series, only a few patients received HDARAC-containing induction treatments. Whether or not the use of HDARAC during induction might improve treatment results can only be assessed by prospective randomized studies. So far, only two randomized studies have compared HDARAC with standard induction therapy while patients of the two arms received the same postremission therapy. 20, 23 In both studies administration of HDARAC containing induction regimens did not improve CR rate and was hampered by an increased toxicity, however disease-free survival of patients receiving HDARAC was significantly longer.
Intensification of post-remission treatment is also likely to contribute to improvement of treatment outcome in younger patients. Over the years the proportion of patients aged less than 60 years who received intermediate-or high-dose AraC containing consolidation followed eventually by an alloBMT, ABMT or PSC transplantation increased in our department. Practice of transplantations extended between the 1980-84 (19 patients), 1985-89 (42 patients) and 1990-95 (50 patients) periods, however most patients aged less than 60 years received chemotherapy as post-remission regimens exclusively. The role of alloBMT or autologous transplantations is better assessed by prospective studies with analyses based on the intention-to-treat principle. When an HLA-identical sibling is available, an alloBMT is generally proposed in first complete remission, despite a high short-term morbidity and mortality, and a long-term impairment of quality of life. 42 The possibility of using allogeneic PSC transplantation might also reduce in the future transplant-related mortality and morbidity and is currently under investigation. 43, 44 There still is controversy as to whether or not to use allo-or auto-transplant as first-line therapy for patients with good prognostic features, since intensive post-remission chemotherapy may offer similar long-term perspectives. Some randomized studies have demonstrated the dose-response effect for cytarabine in patients aged less than 60 years and the interest of HDARAC for consolidation compared to standard dose. 12, 21 In the randomized studies by Cassileth et al 22 and Zittoun et al, 18 HDARAC has been compared to autologous transplantation. In both studies, patients with histocompatible siblings were offered alloBMT whereas the remaining patients were randomly assigned to receive HDARAC or ABMT. Cassileth et al observed no significant difference in DFS beween patients receiving HDARAC and those undergoing alloBMT or ABMT in an intention-totreat analysis. In this study, survival after CR was somewhat better after chemotherapy than after ABMT (P = 0.05) and there was a marginal advantage in terms of overall survival with chemotherapy as compared with alloBMT. Zittoun et al reported that alloBMT and autoBMT resulted in better DFS than intensive consolidation chemotherapy (4-year DFS: 55%, 48% and 30%, respectively, however the overall survival after complete remission was similar in the three groups.
Whether or not outcome of elderly AML patients has improved is more a matter of controversy from one study to another since the influence of selection biases is even more marked in this age group and often precludes any conclusion to be drawn. We observed a significant improvement of the outcome of elderly patients over the years both in terms of CR rate and 5-year OS and an increase in DFS duration although not significant. In our series treatment was restricted to supportive care in 3.4% of patients aged less than 60 compared to 19.3% of elderly patients. In addition, treatment allocation differed significantly according to age: only 10% of patients aged less than 60 years received alternative treatment (suboptimal chemotherapy or differentiating agent) while up to 30% of the treated elderly patients did not receive conventional induction therapy, which within a narrow therapeutic dose range might prove beneficial in patients of this age group. In addition, only 35% of elderly patients received conventional induction following inclusion in clinical trials, while the inclusion rate was of 65% for younger patients. Unfortunately, the retrospective review of patient's reports did not provide precise information about the factors which have influenced decision-making. In a previous study we showed that low inclusion rate in the elderly is inconsistently related to exclusion criteria defined in the protocols. Factors influencing the decision to adopt palliative therapy in AML patients have been analyzed by Neuss et al: 45 in their series this decision was associated with initial treatment off research protocol, older age, female sex, absence of dependent children, antecedent of hematological disorder, but also depended on physicians. We believe that the marked increase over the years in the proportion of patients aged 60 years or more admitted to our department who received conventional induction may partly explain the improvement of outcome we observed for elderly patients. Changes in therapeutic attitudes, especially in elderly AML patients, might be the result of changes in patient-related factors (such as an overall improvement of physical condition, changes in psychosocial factors), as well as a change in physician-related factors (increased willingness to place patients on randomized trials involving intensive therapy, improvement of supportive care).
In conclusion, compared to randomized trials, this historical single center study on a large unselected population of patients avoids selection biases and reflects more accurately the prognosis of AML. In addition, it illustrates the improvement achieved in AML treatment both in terms of CR and overall survival in patients aged less than 60 years, as well as in elderly patients. These results are likely due to intensification of induction and post-remission treatments (with alloBMT or ABMT) in younger patients, administration of conventional induction to more elderly patients, and improvement of supportive care. A number of new therapeutic approaches are being investigated such as treatment regimens aimed at circumventing drug resistance, and might prove to be useful especially in elderly patients and secondary AML whose prognosis remains poor. Prognostic model based on clinical and biologic AML features at presentation that can predict patient outcome should be used to tailor treatment intensity.
